A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis

BACKGROUND: Pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF) can be used in pediatric patients. This study assessed the safety and efficacy of PEG‐rhG‐CSF as a primary prophylactic drug against neutropenia after chemotherapy in pediatric patients with solid tumors or n...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Junting, Lu, Suying, Wang, Juan, Jiang, Lian, Luo, Xuequn, He, Xiangling, Wu, Yanpeng, Wang, Yi, Zhu, Xiuli, Chen, Jian, Tang, Yanlai, Chen, Keke, Tian, Xin, Shi, Boyun, Guo, Lanying, Zhu, Jia, Sun, Feifei, Zhen, Zijun, Zhang, Yizhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358250/
https://www.ncbi.nlm.nih.gov/pubmed/37183837
http://dx.doi.org/10.1002/cam4.6079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358250/
https://www.ncbi.nlm.nih.gov/pubmed/37183837
http://dx.doi.org/10.1002/cam4.6079

Ejemplares similares